SRT3

180.25

-0.66%↓

ORNBV.FI

70.95

+1.14%↑

OPM.FR

12.89

-2.13%↓

GLPG

28.64

+1.99%↑

ICAD

20.78

+1.37%↑

SRT3

180.25

-0.66%↓

ORNBV.FI

70.95

+1.14%↑

OPM.FR

12.89

-2.13%↓

GLPG

28.64

+1.99%↑

ICAD

20.78

+1.37%↑

SRT3

180.25

-0.66%↓

ORNBV.FI

70.95

+1.14%↑

OPM.FR

12.89

-2.13%↓

GLPG

28.64

+1.99%↑

ICAD

20.78

+1.37%↑

SRT3

180.25

-0.66%↓

ORNBV.FI

70.95

+1.14%↑

OPM.FR

12.89

-2.13%↓

GLPG

28.64

+1.99%↑

ICAD

20.78

+1.37%↑

SRT3

180.25

-0.66%↓

ORNBV.FI

70.95

+1.14%↑

OPM.FR

12.89

-2.13%↓

GLPG

28.64

+1.99%↑

ICAD

20.78

+1.37%↑

Search

Laboratorios Farmaceuticos Rovi SA

Closed

SectorHealthcare

53.25 0.47

Overview

Share price change

24h

Current

Min

52.9

Max

53.45

Key metrics

By Trading Economics

Income

-1.2M

22M

Sales

4.8M

160M

P/E

Sector Avg

22.008

40.048

EPS

0.354

Dividend yield

1.64

Profit margin

13.547

Employees

2,188

EBITDA

-107M

31M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+69.33% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.64%

2.45%

Market Stats

By TradingEconomics

Market Cap

94M

2.9B

Previous open

52.78

Previous close

53.25

News Sentiment

By Acuity

50%

50%

175 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2025, 21:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 Aug 2025, 21:21 UTC

Earnings
Major Market Movers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 Aug 2025, 20:45 UTC

Earnings

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 Aug 2025, 19:15 UTC

Major Market Movers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 Aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 Aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 Aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 Aug 2025, 21:30 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 21:21 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 Aug 2025, 21:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss $938M >RIG

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss/Shr $1.06 >RIG

4 Aug 2025, 20:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 Aug 2025, 20:15 UTC

Earnings

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 Aug 2025, 20:13 UTC

Earnings

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 Aug 2025, 20:09 UTC

Earnings

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 Aug 2025, 20:06 UTC

Earnings

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 Aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 Aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 Aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 Aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

69.33% upside

12 Months Forecast

Average 90 EUR  69.33%

High 90 EUR

Low 90 EUR

Based on 1 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

51.1 / N/ASupport & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

175 / 374 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.